Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 7/20 | 0.37 |
| ▸ | CA9 | Q16790 | 7/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21130048 | 0.86 | LMNA (0.43) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL19382510 | 0.84 | LMNA (0.52) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL18798673 | 0.83 | LMNA (0.50) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL21129746 | 0.80 | LMNA (0.45) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL18800054 | 0.80 | KMT2A (0.45) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL18800055 | 0.80 | LMNA (0.45) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL21130046 | 0.78 | LMNA (0.44) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL16574249 | 0.76 | LMNA (0.62) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL18800087 | 0.75 | LMNA (0.53) | LMNAKMT2ACA12CA9CA1 | |
| SCHEMBL12657433 | 0.74 | LMNA (0.53) | LMNAKMT2ACA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322180-B2 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | VISION GLOBAL HOLDINGS LTD. (HK) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322180-B2 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | HBG2, HBG1, HBB | LMNA 382/4885KMT2A 1231/4885CA12 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.